The FDA's usual end-of-year flurry of regulatory approvals is a little lighter than usual, but the agency has delivered some end-of-year cheer to Vanda Pharma after giving the go-ahead to its drug for ...
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The rejection came just a week ...
Vanda is the market leader in tactical positioning and flow data, empowering a growing clientele which today includes the world’s largest investment banks, hedge funds along with central banks, ...
LONDON & NEW YORK--(BUSINESS WIRE)--This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global ...
Combined Business Offers a Unique Portfolio of Must-Have Data, Research and Analytical Solutions With Leading Capabilities in Tactical and Structural Flow and Positioning Analysis Vanda is the market ...
WASHINGTON, Jan. 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's (FDA) ...
Vanda is a high-frequency positioning data and tactical macro insights provider Vanda was FPE’s sixth investment from FPE Fund III Exante Data is based in New York FPE portfolio company Vanda has ...
The FDA's decision on Hetlioz for jet lag disorder cites insufficient evidence despite positive efficacy signals from clinical trials. Legal proceedings previously criticized the FDA's review, leading ...
Vanda Pharmaceuticals also made progress with its treatment for generalized pustular psoriasis (GPP), submitting a Biologics License Application to the FDA for imsidolimab. The application is ...
B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $14 from $11 and keeps a Buy rating on the shares after the FDA approved Nereus for prevention of vomiting induced by motion ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The cost of the approved drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results